Source-grounded facts extracted from Esperion Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Esperion Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: revenue $19.0 million, net income net losses of $55.1 million, EPS $0.81. Guidance reaffirmed.
“Total revenue for the third quarter ended September 30, 2022, was $19.0 million”
J. Martin Carroll was appointed as Chairperson of the Board at Esperion Therapeutics, Inc..
“On June 1, 2022, the Board of Directors (the “Board”) of Esperion Therapeutics, Inc (the “Company”) elected J. Martin Carroll to fill in the newly created vacancy on the Board resulting from an increase in the size of the Board from nine (9) directors to ten (10) directors, effective June 1, 2022.”
Stephen Rocamboli was elected as Director at Esperion Therapeutics, Inc..
“On April 28, 2022, the Board elected Stephen Rocamboli to fill the newly created vacancy on the Board resulting from Dr. McGovern’s resignation from the Board, effective April 28, 2022.”
Mark E. McGovern resigned as Director at Esperion Therapeutics, Inc..
“On April 28, 2022, Mark E. McGovern, M.D. notified the Board of Directors (the “Board”) of Esperion Therapeutics, Inc (the “Company”) of his decision to resign from the Board, effective immediately.”
Richard B. Bartram departed as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer at Esperion Therapeutics, Inc..
“On March 15, 2022, Esperion Therapeutics, Inc. (the “Company”) announced that Richard B. Bartram was stepping down from his positions as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of the Company, effective as of April 8, 2022.”
Eric Warren was appointed as Chief Commercial Officer at Esperion Therapeutics, Inc..
“On March 1, 2022, the board of directors (the “Board”) of Esperion Therapeutics, Inc. (the “Company”) appointed Eric Warren, R.Ph. as the Company’s Chief Commercial Officer pursuant to the terms of an employment agreement with Mr. Warren (the “Warren Agreement”), effective as of March 1, 2022 (the “Commencement Date”).”
Benjamin O. Looker was appointed as General Counsel at Esperion Therapeutics, Inc..
“On January 4, 2022, Esperion Therapeutics, Inc. (the “Company”) announced the appointment of Benjamin O. Looker as the Company’s General Counsel pursuant to the terms of an employment agreement with Mr. Looker (the “Looker Agreement”), effective as of January 1, 2022 (the “Start Date”).”
Seth H.Z. Fischer was elected as Director at Esperion Therapeutics, Inc..
“On October 28, 2021, the Board of Directors (the “Board”) of Esperion Therapeutics, Inc (the “Company”) elected Seth H.Z. Fischer to fill in the newly created vacancy on the Board resulting from an increase in size of the Board from eight (8) directors to nine (9) directors, effective October 28, 2021.”
Daniel Janney resigned as Director at Esperion Therapeutics, Inc..
“On July 28, 2021, Daniel Janney notified the Board of Directors of the Company of his decision to resign from the Company’s Board of Directors, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.